Nama's AI scorecard currently rates Phibro Animal Health Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PAHC's P/E ratio?

Phibro Animal Health trades at a trailing price-to-earnings ratio of 10.1.

When does PAHC report earnings?

Phibro Animal Health's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.94.

What is the PAHC price target?

The median analyst price target from 3 analysts is $49.00, with a range of $37.00 – $55.00.

Is PAHC Shariah compliant?

Nama's AAOIFI-style screen reads Phibro Animal Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does PAHC pay a dividend?

Yes — Phibro Animal Health's dividend yield is 1.5%.

Nama Insights

Phibro Animal Health (PAHC)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Phibro Animal Health (PAHC) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.34B, a trailing price-to-earnings ratio of 10.1 and a free-cash-flow yield of 0.7%. Over the most recent reported fiscal year, revenue grew 17.1% and free cash flow per share fell 76.6%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -12.4% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-45.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.34B
Trailing P/E	10.1
Price / book	3.5
Price / sales	0.9
FCF yield	0.7%
Dividend yield	1.5%
Gross margin	33.8%
Operating margin	12.8%
Net margin	6.6%
Revenue growth (YoY)	+17.1%
Revenue growth (3-yr annual)	+15.8%
EPS growth (YoY)	+53.6%
FCF/share growth (YoY)	-76.6%
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

PAHC earnings

Next report: Feb 3, 2027 (Q2 2027, EPS estimate $0.94). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Nov 4, 2026	$0.79	$0.78	+1.3%	$386.77M
Q4 2026	Aug 26, 2026	$0.85	$0.73	+16.4%	$396.75M
Q3 2026	May 6, 2026	$0.76	$0.71	+7.0%	$383.54M
Q2 2026	Feb 4, 2026	$0.87	$0.67	+29.9%	$373.91M

PAHC analyst price target

Median target $49.00 from 3 analysts, ranging $37.00 – $55.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live PAHC data on Nama Insights →

PAHC FAQ

Is PAHC a buy?: Nama's AI scorecard currently rates Phibro Animal Health Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PAHC's P/E ratio?: Phibro Animal Health trades at a trailing price-to-earnings ratio of 10.1.
When does PAHC report earnings?: Phibro Animal Health's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.94.
What is the PAHC price target?: The median analyst price target from 3 analysts is $49.00, with a range of $37.00 – $55.00.
Is PAHC Shariah compliant?: Nama's AAOIFI-style screen reads Phibro Animal Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does PAHC pay a dividend?: Yes — Phibro Animal Health's dividend yield is 1.5%.